RecruitingNot ApplicableNCT07526571

GLOW Study: Effects of Triple Protein in Women

GLOW Study: A Randomized Trial to Evaluate the Effects of Triple Support Protein on Glucose, Lifestyle, and Overall Well-being in Women


Sponsor

University of North Carolina, Chapel Hill

Enrollment

40 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This single-site, randomized, blinded, placebo-controlled study will evaluate whether 4 weeks of daily Triple Support Protein powder improves glycemic control and overall well-being in healthy women aged 30-60 years. Participants will undergo baseline testing (DXA, fasting blood, standardized meal test with 2-hour glucose and insulin sampling), complete one acute supervised dose, and then consume a daily supplement for 4 weeks. During the final 14 days, participants will wear a continuous glucose monitor. Outcomes include postprandial glucose AUC, insulin sensitivity, and body composition.


Eligibility

Sex: FEMALEMin Age: 30 YearsMax Age: 60 Years

Inclusion Criteria5

  • Females aged 30-60 years.
  • BMI 18.5-40 kg/m\^2.
  • Recreationally active (≥30 min/wk moderate intensity exercise).
  • Healthy and free from disease per health history questionnaire.
  • Willing to abstain from caffeine, tobacco, and alcohol for 24 hours before testing days.

Exclusion Criteria5

  • Currently supplementing whey protein.
  • Pregnant or nursing.
  • Lactose intolerant.
  • Currently using creatine monohydrate.
  • Severe hearing or speech impairment or inability to speak English

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTTriple protein support

Plant based protein + creatine + fiber

DIETARY_SUPPLEMENTPlacebo

Non-caloric matched placebo


Locations(1)

Department of Exercise and Sport Science, Applied Physiology Laboratory

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07526571


Related Trials